Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Tendonitis Treatment Market size was over USD 233.5 billion in 2024 and is estimated to reach USD 365.3 billion by the end of 2037, expanding at a CAGR of 3.8% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of tendonitis treatment is evaluated at USD 242.3 billion.
Globally, the aging population is progressively vulnerable owing to musculoskeletal conditions that include tendonitis, which is the main driving factor for uplifting the market internationally. According to an article published in July 2024 by NLM, the incidence rate of tendon rupture is approximately 2.1 per 100,000 patient years, especially in the United States. Rotator cuff tears is one of the risks associated with the condition, with a prevalence rate ranging from 15% to 20% among the 60-69 years age category, and 37% to 51% among the 80-89 years age category. However, the evolution of conventional and innovative treatment solutions effectively assists in combating the condition, thus boosting the market.
The growth of the tendonitis treatment market depends upon the provision of therapy to patients suffering from any symptoms of the condition. However, the adoption of therapy depends upon the affordability and capability to aid tendonitis in patients. For instance, in an article published by the UT Southwestern Medical Center Organization in August 2022, extracorporeal shockwave therapy (ESWT) is the most advanced therapy to heal from the condition. The organization listed its payer’s pricing as USD 250 per treatment per area approximately. Besides, the implementation of shock wave therapy (SWT) is useful to aid erectile dysfunction which is readily driving the market. However, its pricing strategy varies depending on different areas.
Average SWT Cost
|
Location |
Average Price of SWT per Session |
Average Price of SWT per Treatment Course |
Range of Prices for SWT Treatment Course |
|
Atlanta, Georgia |
USD 372.5 |
USD 2,625.0 |
USD 600.0-USD 4,500.0 |
|
Boston, Massachusetts |
USD 502.5 |
USD 2,912.5 |
USD 1,800.0-USD 4,200.0 |
|
Dallas, Texas |
USD 489.0 |
USD 3,292.3 |
USD 1,800.0-USD 6,900.0 |
|
Los Angeles, California |
USD 612.1 |
USD 3,930.5 |
USD 2,100.0-USD 7,000.0 |
|
New York |
USD 522.0 |
USD 3,330.0 |
USD 1,800.0-USD 16,200.0 |
|
Philadelphia, Pennsylvania |
USD 458.2 |
USD 3,623.7 |
USD 3,000.0-USD 4,500.0 |
|
Washington, D.C. |
USD 497.9 |
USD 3,292.3 |
USD 1,500.0-USD 5,000.0 |
Source: AUA May 2022
Tendonitis Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Rise in the older population: The rise in the aging population is one of the factors readily driving the market growth. According to the October 2024 WHO report, the proportion of the world's population over 60 years will closely double from 12% to 22% by 2050. In addition, approximately 80% of the population will be residing in low- and middle-income nations, thus increasing the demand for treatment options. Besides, reduced physical activity among elder individuals results in muscle imbalances, uplifting the risk of developing tendonitis which eventually is a driving force for the market.
- Increasing implementation of telemedicine: The adoption of telehealth and remote monitoring is another growth factor positively impacting the tendonitis treatment market internationally. According to an NLM article published in March 2024, telehealth accounts for approximately 10% of all outpatient clinic visits worldwide. This makes it a noteworthy growth from pre-pandemic levels and solidifies its position as an ultimate component within abundant clinical service lines and care models. Additionally, more than 78% of physicians advocate telemedicine and in-person visits, thus driving the market upliftment.
Challenges
- Disparities in healthcare accessibility: There is a huge surge of discrepancies in healthcare infrastructures globally which hindering the expansion of the market. Factors such as inadequate access to medical care solutions, specific health professionals, and innovative treatments can deter the timely diagnosis and effective management of tendonitis. Also, financial restrictions in economically disadvantaged communities often prevent individuals from gaining essential medical care, resulting in undiagnosed or untreated cases of tendonitis.
- Overlap in diagnostic tools: The lack of appropriate diagnostic tools such as imaging technologies owing to abrupt healthcare resources is a huge restraint for the market to flourish. In addition, limited access to specialists to accurately diagnose and aid tendonitis with tools leads to inappropriate test results. This eventually creates a barrier for improper treatment solutions that make it difficult to overcome the condition in patients. Further, poor evaluation of machines before being used in diagnostic tools can result in overlapping results leading to inadequate market expansion.
Tendonitis Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
3.8% |
|
Base Year Market Size (2024) |
USD 233.5 billion |
|
Forecast Year Market Size (2037) |
USD 365.3 billion |
|
Regional Scope |
|
Tendonitis Treatment Segmentation
Treatment (Surgery, Therapy)
Surgery segment is set to capture around 75.4% tendonitis treatment market share by the end of 2037. The damage to tendons on the hands and the unsuccessfulness of non-surgical treatment results in the need for surgery to repair and restore the movement in the affected thumb or fingers. As per the 2025 article by WHO, surgical interventions account for approximately 13% of the world’s total disability-adjusted life years (DALYs). Surgical care has gained global popularity as the only possible and effective solution to reduce the risk of disorders, which in turn is a growth aspect for the segment.
Condition (Achilles Tendonitis, Swimmer’s Shoulder, Jumper’s Knee, Pitcher’s Elbow, Golfer’s Elbow, Tennis Elbow)
The Swimmer’s Shoulder segment is expected to impact the tendonitis treatment market at a lucrative rate during the forecast period. As per an article published by NLM in November 2023, the incidence rate of the condition ranges from 3% to 70% internationally. However, with shoulder pain that interrupts the training process of athletes, the incident rate is estimated to be 35% among exclusive and senior-level swimmers. Common treatment options for the condition include stretches and exercise, rest, ice application, implementation of cortisone injections to ease the pain, and utilization of oral anti-inflammatory medications.
Our in-depth analysis of the global market includes the following segments:
|
Treatment |
|
|
Condition |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportTendonitis Treatment Industry - Regional Synopsis
North America Market Analysis
North America tendonitis treatment market is anticipated to capture revenue share of around 44.2% by the end of 2037. As per the 2025 Northshore Organization article, more than 20 million population in the region are subjected to some form of tendonitis, be it plantar fasciitis, Golfer’s Elbow, or Tennis Elbow. However, with the availability of innovations and continuous research and development of healthcare facilities, patients can undergo suitable and effective treatment solutions. As per the March 2023 World Economic Forum statistical report, 50% of people have adopted healthy lifestyles by consuming wholesome food, thereby a positive outlook for the market.
The market in the U.S. has acquired power due to the development of the latest tools suitable for the treatment procedure through approvals of administrative bodies. For instance, in March 2022, TendoNova declared the FDA 510(k) clearance of its new Ocelot surgical tool, which includes the implementation of an innovative technology for disintegration or debridement of soft tissue. The FDA found this tool useful for percutaneous tenotomy in sports medicine, pain management, orthopedics, and podiatry, hence an essential contribution towards the market expansion in the country.
The market in Canada is perceiving substantial progress due to administration-based interventions through the provision of investments in healthcare. According to the November 2022 Government of Canada report, a funding of USD 4.5 million for more than 5 years was approved based on the Pain BC’s project- “Developing a Pain Canada Network and Expanding Best Practice Education and Training Programs Across Canada”. This investment-based strategy enhanced best practices, national collaborations, and expanded resources for patients dealing with chronic pain, thus a positive impact on the market in the country.
APAC Market Statistics
The tendonitis treatment market in APAC is the fastest-growing area and is projected to gain worthwhile development in the forecast timeline. Factors include the high prevalence of tendonitis cases due to the rising geriatric population, sports-based injuries, and busy lifestyles are bolstering the market growth in the region. For instance, a clinical study was issued by NLM in October 2021, wherein 112,350 patients suffered from Achilles tendon rupture, of which 44,248 patients experienced surgical treatment. The prevalence of this condition was extremely high in the age group of 41 to 50 years, thus driving the demand of the market in the region.
The market in India is subjected to effective advancement since the country comprises a variety of hospitals providing medical solutions. In an article published by the Journal of Orthopaedics in January 2023, a clinical study was conducted in a Teaching Hospital in Central India on 252 healthy patients between the age range of 18 and 62 years. Out of these 11.2% comprised the absence of plantaris tendon, either bilaterally or unilaterally. The unilateral absence was among 3.2% and the bilateral was among 4.8%, and overall the absence was among 8%. Thereby, with the provision of appropriate treatment options, the market is readily amplifying in the country.
The tendonitis treatment market in China is achieving revelation due to the increasing presence of medicines and treatment facilities. For instance, in a case report published by NLM in November 2023, a 33-year-old woman from the country suffered from cervical longus tendonitis. There was the provision of acupuncture in combination with massage therapy as a symptomatic treatment option. This treatment continued for approximately 10 days based on which the symptoms improved, and pain was absent in the swallowing movements, especially while consuming water. Therefore, the implementation of such treatments to aid rare tendonitis conditions is highly driving the market growth.
Companies Dominating the Tendonitis Treatment Landscape
- Abbott
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Almatica Pharma, Inc.
- AstraZeneca
- Bayer AG
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Embody, Inc.
- GlaxoSmithKline PLC
- Merck and Co., Inc.
- Paragon 28, Inc.
- Pfizer
- Stryker
- Teva Pharmaceuticals Industries
Companies dominating the tendonitis treatment market are gaining rapid exposure due to an increase in the focus on the development of ground-breaking business growth strategies in the form of product portfolio expansions through government approvals, partnerships and collaborations, mergers and acquisitions, and business footprint expansions. In October 2020, Embody, Inc. declared the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TAPESTRY biointegrative implant for tendon and ligament repair.
TAPESTRY is a bioengineered collagen-based implant with a registered micro-architecture precisely designed for tendon and ligament repair. With preliminary capital through the Defense Advanced Research Projects Agency (DARPA) Atoms to Products Program, Embody has established additive manufacturing and progressive biofabrication techniques to accumulate collagen from the molecular scale to produce bioengineered medical devices explicitly designed for soft tissue repair. Therefore, such approvals leading to the latest innovations is highly driving the tendonitis treatment market globally.
Here's the list of some key players:
In the News
- In January 2024, Paragon 28, Inc. declared the launch of the Mister Tendon System, allowing surgeons to execute a distal cut of the flexor hallucis longus or flexor digitorum longus tendon through a marginally invasive incision, garnering a working length of tendon suitable for tendon transfer procedures.
- In September 2021, Stryker’s Trauma & Extremities division unveiled its Citrelock Tendon Fixation Device System to provide surgeons a distinguished design via a tendon thread featuring a resorbable technology, known as Citregen, that has exclusive chemical and mechanical properties for orthopaedic surgical applications.
Author Credits: Rajrani Baghel
- Report ID: 7346
- Published Date: Mar 18, 2025
- Report Format: PDF, PPT
